SGB-9768

N/A

Report date: 2026/05/14 15:49:36
NME

Base Information

Drug NameSGB-9768
Drug Alias Namea chemically synthesized double-stranded oligonucleotide directed against C3 messenger RNASGB-9768
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsC3 glomerulopathyComplement-Mediated DiseasesGlomerulonephritis, Membranoproliferative +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Sanegene Bio Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSanegene Bio New Zealand LtdSuzhou Sanegene Bio Inc
Inactive CompaniesN/A
Active IndicationsC3 glomerulopathyComplement-Mediated DiseasesGlomerulonephritis, Membranoproliferative +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A